JANX

Janux Therapeutics, Inc. (JANX) PESTLE Analysis Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Political

No material political developments were reported this month.

Economic

The company remains in a cash-rich but unprofitable position, with a current ratio of 16.35 and net debt to EBITDA near zero, but valuation remains elevated at 33.30x EV/Sales while free cash flow is still negative.

Social

No material social or customer-demand changes were reported this month.

Technological

R&D intensity remains very high at 3.89x revenue, indicating continued investment in the pipeline, but there was no new product or clinical update in the news flow.

Legal

No material legal or litigation developments were reported this month.

Environmental

No material environmental developments were reported this month.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Janux Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →